Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gevokizumab in Erosive Osteoarthritis of the Hand
NCT02293564Phase 2Completed
- Sponsor
- XOMA
- Start
- Mar 2013
- Primary completion
- Jan 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of gevokizumab in erosive osteoarthritis of the hand (EOA), sponsored by XOMA. Started Mar 2013; status: completed.
02
Drugs
gevokizumab
03
Conditions
erosive osteoarthritis of the hand (EOA)
Beyond the preview
Go deeper on NCT02293564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02293564.